Abstract
Widespread resistance to our arsenal of antibiotics is no longer a threat — it is reality. With no new antibacterial drugs expected to reach the market any time soon, immediate action is needed to avert a looming healthcare disaster. But antibacterial discovery faces immense scientific and business challenges. What needs to be done to turn the tide? As part of this special Focus issue on Antibacterials, Nature Reviews Drug Discovery asked representatives from industry, academia, the FDA and the clinic working on different aspects of antibacterial research to give their own perspectives on where the next generation of antibiotics will come from.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
A call to arms. Nat Rev Drug Discov 6, 8–12 (2007). https://doi.org/10.1038/nrd2225
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2225
This article is cited by
-
Identifying producers of antibacterial compounds by screening for antibiotic resistance
Nature Biotechnology (2013)
-
Culturable rare Actinomycetes: diversity, isolation and marine natural product discovery
Applied Microbiology and Biotechnology (2013)
-
Thoughts and facts about antibiotics: Where we are now and where we are heading
The Journal of Antibiotics (2012)
-
Nanomechanical detection of antibiotic–mucopeptide binding in a model for superbug drug resistance
Nature Nanotechnology (2008)
-
Engineering Conferences International (ECI) Natural Products Discovery and Production II
The Journal of Antibiotics (2008)
